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Visceral hypersensitivity is the heightened response to sensory stimuli.  Visceral 
sensations are transmitted through primary afferent neurons in the dorsal root ganglion 
(DRG) and the sensitization of the neural pathway leads to modification in spinal 
ascending and descending neurons. The aim of this investigation is to determine the effects 
of brain-derived neurotrophic factor (BDNF) and its signaling pathway on sensory 
neuronal activation during colitis. In order to evaluate this, levels of calcitonin-gene related 
vii 
 vii 
peptide (CGRP), a neuropeptide marker for nociceptive transmission, and phosphorylated 
cAMP-response element binding protein (pCREB), a molecular switch in neuronal 
plasticity, were studied in response to BDNF in vivo and in vitro. Colitis caused an 
increase in the levels of CGRP and pCREB in thoracolumbar DRG, which was attenuated 
by BDNF neutralizing antibody and PLC inhibitor, U73122, but not PI3K inhibitor, 
LY294002. BDNF-induced CGRP expression and CREB activation in DRG culture was 
also blocked by PLC inhibitor, U73122, but not PI3K inhibitor, LY294002, or MEK kinase 
inhibitor, PD98059. These results suggest a unique signaling pathway, i.e. the PLC-γ 
pathway, is mediating BDNF action on sensory neuronal activation during colitis. 
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Introduction 
  
1.1 Inflammatory Bowel Disease 
In 1859, Sir Samuel Wilks was the first to describe inflammatory bowel disease (IBD), 
specifically ulcerative colitis, in his account of his patient, Isabella Bankes. In this account, he 
wrote: 
In the small intestine nothing remarkable was observed until the lower end of the ileum 
was reached, when at about three feet from its termination in the caecum, the mucous 
membrane commenced to exhibit an inflammatory response. In the caecum, inflammation 
of the most acute and violent character was observed…[11] 
 
Wilks’s diagnosis was later amended to Crohn’s disease in the mid-1950s. This description, 
however, inaugurated documentation in the late 19th century of the two main forms of 
inflammatory bowel disease: Crohn’s disease (CD) and ulcerative colitis (UC).  
 Today, the prevalence of these diseases is widespread, most commonly found in Europe 
and North America [4, 6].  In Europe, the reported incidence of CD is 322 per 100,000 persons 
and 505 per 100, 000 person for UC [7]. The prevalence in North America for CD is 319 per 
100, 000 persons and 249 per 100,000 persons [7]. Four percent of IBD cases are not 
distinguishable between UC and CD; these cases are termed indeterminate colitis [2, 4, 10]. The 
incidence of IBD is similar between men and women, and it also does not differ significantly by 
race [7].  Increased risk of IBD rises with age, peaking at early adulthood [7]. The prevalence 
and incidence of UC and CD is increasing with time and in different regions of the world, which 
points towards its development as a global disease.  
 Ulcerative Colitis is a relapsing, debilitating inflammation focused on the colon. In the 
United States alone, 12 cases for every 100,000 persons is the annual prevalence for this disease 
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[1]. Endoscopic biopsy is the evaluative procedure used to confirm diagnosis [1]. The exact 
etiology of UC is yet unknown, although there are links to genetic and environmental factors [1, 
2, 5]. Family occurrence reflects a genetic tendency to acquire the disease, but there is no gene or 
antigen present invariably in all patients [5]. Causes of UC have been linked to acute bacterial 
infections, yet no particular pathogens have been identified [8]. Patients demonstrate 
immunological abnormalities, suggested to be a result of inherited reactions to environmental 
elements [8]. Individuals with this disease exhibit symptoms such as diarrhea, excretion of pus, 
mucus, or both, and abdominal cramping [1, 5, 8]. The initiation of symptoms can be sudden or 
gradual and one-third of patients can present with extraintestinal symptoms such as arthritis, 
psoriasis, and uveitis [5, 8]. Regions of inflamed lesions are diffuse and superficial and also 
present in an uninterrupted fashion in the colon [1, 5]. As the disease progresses, there are flares 
that accompany periods of remission. Predicting the degree of inflammation and response to 
treatment is difficult because of the variability of the disease [1,5].  In young children, flares can 
be severe and unresponsive to medication [8]. Thus, much remains to be discovered in the 
pursuit of diagnosis and treatment of UC. 
 Crohn’s disease is also a relapsing inflammatory disorder, but differs from UC in that it 
can affect the entire gastrointestinal tract [10]. It presents, however, mostly in the ileum and 
colon [3]. Compared to normal colon, there is intense swelling, inflammation, ulceration, and 
scarring. Symptoms of CD are diarrhea, abdominal pain, and fatigue. Strictures and fistulas, 
however, can form without any symptoms for years [2]. Inflamed lesions of mucosa can be 
intermittent with normal tissue and there are extraintestinal symptoms similar to those of UC [3].  
It is evident that Crohn’s disease can be a debilitating and life-threatening inflammatory bowel 
disorder. 
10 
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 Treatments of inflammatory bowel diseases can be divided into enzymatic and non-
enzymatic approaches. These target potential causative factors such as reactive oxygen species, 
immune dysregulation, and pathogenic bacteria [12]. These treatments have found to be only 
slightly effective in inflammation and higher doses may alleviate symptoms of oxygen reactive 
disorder [12]. Further studies on possible novel treatments include enzymatic therapies, and use 
of eukaryotic and bacterial cell delivery systems.  
 
1.2 Visceral Hypersensitivity in the Dorsal Root Ganglion 
Chronic pains, such as those of 
inflammatory bowel disease, have 
multifaceted problems, which have no 
straightforward infectious, metabolic, or 
anatomical basis. These bowel disorders, 
despite variations in cause and symptoms, 
all demonstrate lower abdominal pain. 
Visceral hypersensitivity, or visceral 
hyperalgesia, denotes a term used for expressing the enhanced sensation of visceral organs to 
stimuli [17]. Improper signaling in the viscera through the sensory reflex pathway can be a chief 
cause for abdominal pain [17]. Sensitization of the neural pathway, involving primary afferent 
neurons and spinal descending neurons, transmits visceral sensations to the supraspinal level and 
the maladaptation of descending pathways modulate spinal signaling (Figure 1) [14, 17].  
Visceral organs in the thorax and abdomen, except for the pancreas, are innervated by 
both parasympathetic and sympathetic projections [13]. The primary sensory afferents are 
Figure 1. Projections of Spinal afferents to visceral organ and 
central nervous system. Primary afferent neurons are pseudounipolar 
cells that have axonal processes that project to the visceral organ and 
also have processes that project to the spinal cord from the DRG. 
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pseudounipolar cells that have visceral points of connection as well as central axonal processes. 
In humans, the lumbar splanchnic nerve (LSN) and hypogastric nerve (HGN) from 
thoracolumbar outflows and the pelvic nerve (PN) from sacral outflows innervate the small and 
large intestine and the urogenital organs [13, 19]. The peripheral projections terminating on the 
visceral organ may innervate intramuscular arrays (IMAs), which are vagal mechanoreceptors on 
gastrointestinal smooth muscle [16]. This placement of visceral afferent neuron terminals allow 
for response to luminal and local chemical stimuli, as well as to mechanical (usually distending) 
stimuli. Projection on the other side of the afferent allows for central processes to enter the spinal 
cord through nodose ganglia or dorsal root ganglia (DRG), projecting mainly to lamina I and 
laminae V–VII [19]. The cell bodies of primary visceral afferent neurons are in the nodose 
ganglia, for vagal afferents, and the DRG, for spinal afferents, from which the information is 
carried further along the central nervous system in the spinal cord and brainstem [17, 19]. 
Primary visceral afferents have been shown to have a role in both acute and persistent 
pain contributing to the development of hyperalgesia. Visceral afferents have a high- and low-
threshold response for visceral mechanosensation, which is primarily a result of organ distension 
[14]. “Silent,” or mechanically insensitive, visceral afferents seem to acquire spontaneous 
activity after tissue injury. It is not known the exact mechanism behind these afferent 
awakenings, whether it is due to experimental distention stimuli or if they are actually 
mechanically insensitive [14]. These afferents also could represent a group of chemonociceptors 
that become active after tissue insult and demonstrate polymodal sensitivity to different forms of 
sensory information [14]. The presence of these fibers in large quantities could suggest in 
increased torrent of afferent input, impacting visceral hyperalgesia [14].  
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Low-threshold visceral afferents have been shown to sensitize after experimental organ 
inflammation. Increased sensitization after inflammation signifies an increase in response 
magnitude, increase in spontaneous activity, and/or a decrease in response threshold [14, 19]. 
Biochemical mediators originating from immune and non-immune cells could factor into 
sensitization of the extrinsic visceral sensory innervation, molecules including amines, peptides, 
products of arachidonic acid metabolism, cytokines, neurotrophins, and reactive metabolites 
[19]. Thus, these mechanisms in response to inflammation could contribute to visceral 
hyperalgesia and enhanced sensitivity to normal contents.   
Visceral pain cannot be exactly mimicked in animal models because of its wide-ranging 
nature; however, experimental models have been developed in rats and mice. Instillation of 
2,4,6-trinitrobenzene sulfonic acid (TNBS) into rat colon provides an inflammatory model of 
colitis that closely parallels pain in human patients [18, 19]. TNBS is a hapten, a small molecule 
able to elicit an immune response by binding to antibodies when coupled to a carrier [15]. When 
rats are induced with TNBS, they present with ulcerative colitis-like symptoms [19]. Peak 
inflammation occurs 4 to 5 days after induction and remains for about a month [18]. They 
present with hypersensitivity to colonic distention and visceral hypersensitivity persists up to 16 
weeks after the initial inflammation has been alleviated [18]. This model provides a foundation 
upon which to study the biochemical mediators involved in visceral hypersensitivity.   
In summary, signals originating from the visceral organ are directed to extrinsic primary 
afferent sensory neurons in the DRG and/or the nodose ganglia. The information is processed 
and passed to higher processes in the central nervous system (CNS), after which descending 
nerves transfer excitatory or inhibitory signals that alter visceral organ function. The primary 
afferents demonstrate neuronal plasticity in response to biochemical stimuli and various 
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circumstances, which result in alteration of anatomical, biochemical, and electrophysiological 
characteristics of neurons.  
 
1.3 Neurotrophins  
 
The neurotrophin family is generally recognized to provide neuroprotection, synaptic 
plasticity, and neuronal cell development. Its members are vital mediators for neuronal activity 
in both the central and peripheral nervous system. 
There are four main mammalian neurotrophins: Nerve 
Growth Factor (NGF), Brain-Derived Neurotrophic 
Factor (BDNF), Neurotropin-3 (NT-3), Neurotropin-
4/5 (NT-4/5). The receptors for each neurotrophin are 
tyrosine kinase A (TrkA) binding to NGF, TrkB 
binding to BDNF or NT-4, and TrkC binding to NT-3. 
Under certain conditions, NT-3 can also stimulate 
TrkA and TrkB (Figure 2) [17].  
The general neurotrophin receptor (NTR) p75 
bind to all the neurotrophins with low affinity when present alone in cells (Figure 3) [17, 26]. 
High-affinity binding between p75NTR and neurotrophins in the presence of the Trk receptor 
increases cell receptiveness. The response of neutrophin/p75NTR/Trk complex is cell growth and 
survival signals (Figure 3). The contact between Trk receptors and p75NTR increases the affinity 
of Trk to various ligands that heighten cell growth and survival mechanisms through the 
stimulation of the phosphoinositide 3-kinase (PI3K)/Akt pathway or the mitogen-activated 
protein kinases (MAPK)/extracellular signal-regulated kinases (ERK) pathway [17, 25, 26]. On 
Figure 2. Major neurotrophins and their 
receptors. A. NGF Binds to TrkA, BDNF bind to 
TrkB and NT-3 binds with high affinity to TrkC, 
with low affinity binding to TrkA and TrkB. B. 
Proneurotrophins and neurotrophins also bind to 
p75NTR. 
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the other hand, proneurotrophins, the uncleaved precursors to neurotrophins, can bind to p75NTR 
in the presence of sortilin and this complex leads to activation of apoptosis through the c-Jun N-
terminal kinases (JNK), nuclear factor κ-B (NFκB), or Rho pathways (Figure 3) [17, 24]. These 
pathways, in turn, promote inflammatory responses. Another important pathway is the 
phospholipase C gamma (PLCγ) pathway, a signal cascade allows for calcium and sodium influx 
through ion channels that leads to long-term potentiation (LTP) and neuronal plasticity in CNS 
[17].  
Thus, neurotrophins are important mediators that 
promote cell function through two primary means.  One, 
they activate signal transduction cascades at the nerve 
terminal, and two, they are involved in the retrograde 
transport of signal mediators from nerve terminals to 
cellbodies [17]. Another form of transmission is 
anterograde transport where molecules are transported 
from the cell body to axonal terminals. The primary 
afferent sensory fibers have neurons that signal complex 
nociceptive and non-nociceptive changes in visceral 
organs [26]. Neurotrophin expression and distribution 
depend on different factors of cell type and development. For small-diameter primary sensory 
neurons of neural-crest origin of rats, NGF is essential for neuronal survival; however, as these 
animals mature, the cells become less dependent on NGF and change their expression of 
neurotrophic factor receptors [23]. BDNF interacts with these sensory neurons in maturity and it 
Figure 3. p75NTR receptor binding and 
effects. When NGF binds to the dimerization 
of TrkA and p75NTR, signaling pathways 
promote synaptic plasticity, differentiation, and 
neuronal growth. However, when 
proneurotrophins, pro-NGF, in the presence of 
sortilin, binds to the TrkA/p75NTR heterodimer, 
apoptosis ensues. 
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important for regulating mechanosensitivity of adapting touch mechanoreceptors [23], 
demonstrating BDNF’s crucial role in sensory neuron development.   
 
1.4 Brain-Derived Neurotrophic Factor (BDNF)  
 
In 1982, through experimental investigation, it was shown that BDNF enhances the survival 
of cultured peripheral sensory neurons and enhances the survival of DRG and nodose ganglia 
neurons. BDNF is a basic protein initially isolated from pig brain and has a molecular weight of 
12.4 kDa [30]. BDNF binds to TrkB and although most biological functions are attributed to the 
binding of full-length TrkB, some roles have been suggested for the truncated receptor as well 
[31]. BDNF and TrkB receptor have a wide distribution across the central nervous system. In the 
early stages of development, experimental transgenic mice have shown that BDNF plays a 
significant role in the cell survival of sensory neurons [31].  
BDNF, like its other family members, can be retrogradely transported in sensory neurons [17, 
23]. It has been shown that it can be transported to both of the peripheral nerve fibers and the 
spinal cord where it accumulates in the central terminals in the superficial laminae (I and II) [23].  
The superficial laminae of the spinal cord are important sites for processing of nociceptive 
information. It was found that BDNF protein is localized mostly in the primary sensory 
nociceptors, in those that express TrkA and are sensitive to NGF [20]. In these neurons, BDNF is 
stored in dense core vesicles, possibly released in response to nociceptor acitivty [21].  
BDNF has been shown to increase the frequency of excitatory post-synaptic currents in 
Xenopus cultures [27]. BDNF, in general, seems to heighten excitatory (glutamatergic) synapses 
and weaken inhibitory (GABAergic) synapses. This neurotrophin is an important 
neuromodulator in pain transduction. It is synthesized by the dorsal horn and in response to 
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inflammation injury in the peripheral nerves, BDNF is significantly upregulated [28]. BDNF 
sensitizes nociceptive afferents and causes hyperalgesia. It has been found that exogenous BDNF 
treatment increases nociceptive spinal reflex activity in rat spinal cord and that addition of BDNF 
inhibitors reduced the hyperalgesia. Kerr, et al. demonstrated that this spinal reflex was reduced 
when spinal cord was treated with BDNF-sequestering antibody TrkB-IgG [29]. This group also 
showed that endogenous BDNF affects behavioral nociceptive responses as well [29].  
Conditional mouse knockouts deleting BDNF showed that null animals were healthy with no 
reduction in sensory neurons, but pain-related behaviors were significantly affected [32]. It was 
determined from these knockout mice that BDNF plays a crucial role in regulating inflammatory 
pain thresholds [32]. Studies have shown that MAP kinases ERK and p38 are important in the 
signal transduction cascade upregulating BDNF in these pain-related behaviors [33].  Increased 
phosphorylation of ERK in lamina I of the dorsal horn has been shown in neurons transmitting 
pain hypersensitivity. Regulation of these signaling cascades plays a crucial role in the 
expression of BDNF in pain-transducing neurons [34].  
 
1.5 BDNF signaling cascades 
 
BDNF has significant roles in cell differentiation, growth, survival, neuronal branching, and 
strengthening synaptic function [35, 36].  Effects of BDNF are also coupled to LTP in the 
hippocampus through autophosphorylation of the TrkB receptor, activating the Ras/ERK, 
phosphatidylinositol 3-kinase/AKT, or PLC-γ pathways (Figure 4) [37].  
 Activation of the Ras/ERK beings when a tyrosine residue on the Trk receptor is 
phosphorylated and the receptor then binds to adapter proteins, such as Shc, Grb2, and Sos [39]. 
GDP is exchanged for GTP and this leads to activation of the protein Ras, which in turn activated 
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a number of kinases, such as Raf and MEK [40]. MEK then activates MAPK, which then is 
navigated to the nucleus where it can activate transcription factors such as Elk1 [40, 41]. Elk1 
binds to the serum response factor, which is linked to the serum response element [42]. Ras can 
also phosphorylate and activate a number of kinases, which translocates to the nucleus and 
activates kinases [38, 42]. CREB then links to the cAMP-Ca response element (Ca-CRE) and 
activates transcription of immediate early 
genes with the assistance of the SER 
complex [43]. 
 The PLC-γ pathway can interact 
with the Ras pathway to activate ERKs . 
TrkB can also couple with PLC-γ to 
produce high frequency stimulation in 
association with LTP [44]. The postulated 
mechanism of action in the interaction of 
PLC-γ with MEK is due to an inositol 
triphosphate (IP3)-mediated increase in 
intracellular calcium or diaccylglycerol 
(DAG)-induced activate of protein kinase C 
(PKC) [45, 46].   
 Another mechanism linked to Trk 
autophosphorylation is the PI-3 kinase pathway [45].  This pathway regulates many second 
messenger molecules, which in turn activate kinases, such as Akt, a protein that mediates most of 
the pathways effects [47].  The activation of Akt can lead to downstream effects, such as cell 
Figure 4. Major signaling pathways of BDNF. Shown are the 
signaling cascades of the three major pathways of neurotrophin 
signaling: Ras/ERK (purple) , phosphatidylinositol 3-kinase/AKT 
(red), or PLC-γ (orange). Each pathway activated by the binding of 
BDNF and the autophosphorylation of the Trk receptor can lead to 
activation of different transcription factors and alteration of gene 
transcription 
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survival, development, and proliferation. This pathway has been shown to activate the NFKB 
pathway that promotes cell survival and also downregulate the JNK/p38 pathway which leads to 
apoptosis (48, 49).  
 Thus, activation of Trk receptor through autophosphylation can lead to multiple cellular 
responses and activation of many signaling molecules. Kinetics, strength of signal, and the DNA-
binding affinity of certain factors all contribute to the downstream activity of the BDNF 
signaling [26]. Activation of certain promoters for transcription may require the concurrent 
presence of many different transcription factors [49]. Understanding the signaling pathways is 
important for the understanding of how pain behaviors are molecularly transmitted.  
1.6 cAMP-Response Element Binding Protein (CREB)  
CREB is a transcription factor that regulates an estimated 4,000 genes in humans and has 
been found to be involved in the perpetuation of neuropathic pain, inflammation pain, and 
chronic muscle pain [64-66].  Furthermore, inflammation-induced nociceptive behavior has been 
shown to associate with the phosphorylation of CREB (pCREB) [67-68]. This transcription 
factor is shown to be extensively involved in synaptic plasticity and long-term potentiation [70]. 
Activation of CREB is complex and may involve many different signaling molecules. More than 
300 stimuli are suggested to phosphorylate CREB through intensification of Ca2+ pathways and 
activation of kinases that phosphorylate CREB on serine 133 [69]. CREB could serve as an 
important mediator between extracellular signaling and regulation in gene transcription to 
nociceptive pain transmission.  
1.7 Calcitonin-Gene Related Peptide (CGRP) 
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Calcitonin-Gene Related Peptide (CGRP) is a meaningful neuropeptide marker in the 
biochemical response to pain perception. It is a 37 amino acid peptide and there are two types 
isolated so far: CGRP-α (CGRP-I) and CGRP-β (CGRP-II) [50]. CGRP expression has been 
implicated in many systems including learning and memory [58], opiod tolerance and addiction 
[59], and pain transduction in the PNS and CNS [60]. It is found in a variety of nociceptive 
hypersensitivity mechanisms. Zhang et al. found that CGRP-α knockout mice were unable to 
develop hyperalgesia after induction of knee inflammation. Studies in rats and mice have helped 
to determine that CGRP plays in an important nociceptive role in neurogenic plasticity during 
peripheral inflammation [52, 53]. CGRP is rich in small-diameter unmyelinated neurons and 
considerably less so in medium- to large-diameter neurons [50, 54]. After induction of an 
inflammatory response, CGRP is upregulated significantly in primary afferent sensory neurons 
[55].  
Recent studies have shown that colitis-induced rat DRG have increased mRNA and 
protein CGRP expression in the L1 segment [61]. There appears to be differential expression of 
CGRP along different thoracolumbar DRG and this could be due to divergent projections of 
sensory afferent fibers [61]. L1, L2, L6, and S1 DRG segments in rats have been shown to 
possess colonic primary afferent fibers [61, 62]. Another study has shown that retrograde NGF-
induced CGRP expression operates through the extracellular signal-related protein kinase (ERK) 
pathway leading to CREB activation, leading to nociceptive transmission and facilitation of the 
sensation of inflammatory pain [63]. There appears to be an NGF-CREB-CGRP signaling axis 
and understanding the mechanism of neurotrophic signal transduction in response to 
inflammatory pain is a considerable stride in tackling what is unknown about sensory 
hypersensitivity from visceral inflammation.  
20 
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1.7 Summary	  
Previous studies have shown that BDNF increases in lumbosacral DRG in response to 
inflammation. [71]. However, the mechanism through which BDNF regulates synaptic changes 
and neuropeptide expression in colitis is not heavily studied. Extending from these previous 
studies, the goal of this study is to understand how inflammation-induced increase in BDNF 
regulates sensory neuron activation. 
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Objectives and Aims 
 
Objectives  
The objective of this study is to characterize the role of BDNF in sensory neuronal 
activity by examining CREB phosphorylation and CGRP expression in sensory neurons during 
colonic inflammation and to evaluate the signaling pathways that regulate these events.  
Hypothesis 
Colitis-induced sensory neuronal activation is mediated by endogenous BDNF through 
one or more signaling pathways. 
Aims 
Aim 1: Characterize the role of BDNF on CREB activation and CGRP expression in colitis. 
Aim 2: Characterize the role of BDNF on CREB activation and CGRP expression in DRG 
culture. 
Aim 3: Study the signaling pathways involved in vitro and in vivo. 
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Methods 
 
3.1 Experimental Animals 
Adult male rats weighing 150–200 g were used for all studies. All experimental protocols 
involving animal use were approved by the Institutional Animal Care and Use Committee at the 
Virginia Commonwealth University (IACUC # AM10315). Animal care was in accordance with 
the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) and 
National Institutes of Health guidelines. All efforts were made to minimize the potential for 
animal pain, stress or distress as well as to reduce the number of animals used. 
3.2 Introduction of Colonic Inflammation in Rats with TNBS and Ganglia Dissection 
 
Colonic inflammation was induced in rats by instillation of trinitrobenzene sulfonic acid 
(TNBS: 1.5 mL/kg of 60 mg/mL solution in 50% EtOH). Control animals received 50% EtOH. 
Rats were killed on day 3 or 7 following the induction of colitis. All injections were performed 
when rats were anesthesized under isoflurane (2%). Following sacrifice, rats were perfused with 
Krebs buffer and then 4% paraformaldehyde for use in immunohistochemistry. The L1, L2, L6, 
and S1 DRGs were removed for cryosectioning.  
For BDNF in vitro studies, naïve animals were sacrificed and thoracolumbar DRG 
dissected. Membranous capsules surrounding the ganglia were then peeled away using fine 
forceps and DRG were then incubated in Dulbecco's Modified Eagle Medium (DMEM) for 2 
hours. Inhibitor solutions were added one hour prior to BDNF stimulation. Following 
stimulation, DRG were prepared for western blot or immunohistochemistry. DRG were 
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processed for immunohistochemistry by transfer to 4% paraformaldehyde for 4-6 hours; and 
ganglia were then stored in 20% sucrose overnight.  
3.3 Introduction of Antagonists in TNBS-induced Animals 
 Endogenous BDNF was blocked by 36 µg/kg of BDNF neutralizing antibody (anti-
BDNF) through intravenous administration. In order to inhibit the PI3K pathway in vivo, an 
intraperitoneal injection of a PI3K inhibitor, LY294002 (Calbiochem), at a single dose of 50 
µg/kg body weight was made 3 to 4 days after TNBS induction. To inhibit PLC pathway, 
animals were injected with U73122 at a dose of 1mg/kg body weight.  Both U73122 and 
LY294002 solution was prepared by dissolving in DMSO as stock and then diluting in saline for 
injection. For in vitro studies, inhibitor concentrations of 5 µM for U73122, LY2944002, and 
PD98059 were added to DMEM solution one hour into ganglia incubation.  
3.4 Quantitative Real-Time PCR (qPCR) 
After animal sacrifice, L1 DRG was homogenized in lysis buffer using instructions 
according to RNAqueous kit (Ambion, TX) and total RNA was extracted. The total RNA in 
buffer then underwent reverse transcription using High Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems, ABI) under manufacturer’s instruction. The cDNAs then were mixed 
with specific Taqman probes and PCR master mix (Applied Biosystems, ABI). qPCR was 
performed on StepOnePlus Real-Time PCR System (Applied Biosystems, ABI) with SYBR 
Green as the indicator. The target gene was calcitonin gene-related peptide (CGRP). β-Actin was 
used as an endogenous control. The changes in the target genes were normalized against the 
endogenous control and then were calculated to express fold changes using 2−ΔΔCt.  
3.5 Immunohistochemistry 
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 Ganglia were transferred from 20% sucrose and embedded in OCT cryostat medium 
(Tissue Tek). Each ganglion was then sectioned at a 20 µm thickness and placed on gelatin-
coated slides. Slides were then heated at 30oC for two hours. Slides were then incubated 
overnight with antibodies against CGRP (1:2000, Abcam), p-CREB (1:1000, Cell Signaling), p-
Akt (1:500, Cell Signaling), and PLC-γ (1:1500, Santa Cruz Biotechnology) at room temperature 
in 5% normal donkey serum and 0.3% Triton buffer. Following incubation, slides were washed 
with a 0.1M sodium phosphate buffer at a pH of 7.4 thrice for ten minutes each. Slides were then 
incubated with a fluorescent species-specific secondary antibody. Excess antibody was washed 
with the 0.1M sodium phosphate buffer thrice at ten minutes each cycle. Citiflour anti-fadent 
mounting medium (Electron microscopy Science) was then added to slides before cover-slipping. 
Slides were viewed with an Axiocam Carl Zeiss microscope and neurons exhibiting 
immunoreactivity greater than the observed background level were considered positively stained. 
The area of the DRG section was measured using spline tool, giving an area in micrometer 
squared, and number of positive neurons in the outlined area were counted. Numbers were then 
converted to millimeter squared Area and positive cells were totaled for one image and all 
images were averaged to give final number of positive cells per millimeter squared. For co-
localizations, slides were double-stained according to the procedure above and photos were 
processed with Adobe Photoshop software. 
3.6 Western Blot 
 Ganglia were homogenized in T-Per solution (Pierce Biotechnology, Rockford, IL) with 
addition of protease and phosphatase inhibitor cocktails (Sigma). Protein extract was added to an 
equivalent amount of Laemmli Sample Buffer (Bio-Rad). Proteins were then separated on a 10% 
SDS-PAGE gel and transferred to a nitrocellulose membrane using Trans-Blot Turbo (Bio-Rad). 
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The membrane was blocked using 5% milk in Tris-buffered saline (TBS), washed thrice for ten 
minutes with TBS and 0.1% Tween-20 (TBST) solution, and incubated at 4oC with primary 
antibody against p-CREB (1:1000, Cell Signaling). Excess primary was washed thrice for ten 
minutes each cycle with TBST and incubated with a horseradish peroxidase (HRP) conjugated 
secondary antibody (1:2000, Cell Signaling) at room temperature. After washing, membranes 
were covered in West Femto Maximum Sensitivity Substrate (SuperSignal) to activate HRP 
enzymatic activity for observation of bands on x-ray film. For endogenous control, the same 
membrane was stripped and re-incubated with anti-β-actin (1:2000, Sigma). The bands were 
visualized using ODYSSEY infrared imaging system (Li-cor Bioscience). 
 3.7 Statistical Analysis 
 Results of each study are shown as the mean ± SD. Control and experimental groups 
were compared by ANOVA with differences between means considered significant at p ≤0.05. 
When two groups were compared, a t-test was used. GraphPad Prism 6 was used for analysis. 
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Figure 5. Animal models used for tissue dissection. A. TNBS-induced animals sacrificed after 
designated time and tissues collected for immunohistochemistry (IHC) and RT-PCR. B. 
Immunohistochemistry and western blot were used to analyze in vitro studies.
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Figure 6. Rat spinal cord and DRG. DRG and spinal cord were dissected out after sacrifice and 
analyzed according to experimental design.   
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Results 
 
 
4.1 BDNF increases CGRP expression in DRG neurons during colitis and in DRG culture 
 
 In colitis, it was determined through immunohistochemistry that DRG had an increased  
(p < 0.05) protein expression of CGRP and this inflation was attenuated significantly (p < 0.05) 
by treatment with anti-BDNF (Figure 7). In order to investigate whether anti-BDNF affects 
CGRP mRNA expression, RT-PCR was performed on three-day colitis-induced DRG. mRNA 
analysis after three-days induction was chosen over seven-days in order to accurately assess 
expression before protein translation and it was reported previously that at this time point CGRP 
mRNA was increased in the DRG [62]. It was determined that anti-BDNF reduced heightened 
CGRP mRNA transcription due to colitis (Figure 8).  Further exploration of the role of BDNF on 
CGRP expression was conducted in culture through incubation of DRG explants with BDNF. 
Immunohistochemical analysis determined that BDNF significantly increased (p < 0.05) CGRP 
protein expression in vitro (Figure 9).   
4.2 Signaling pathways in BDNF-induced CGRP expression in culture 
 
 To examine the signaling pathways through which BDNF leads to CGRP expression, 
DRG explants treated with BDNF were also treated with signal cascade inhibitors. 
Immunohistochemistry showed that in vitro treatment of DRG with PLC inhibitor, U73122, 
decreased (p<0.05) BDNF-induced CGRP protein accumulation (Figure 10). MEK kinase 
inhibitor, PD98059, and PI3K inhibitor, LY294002 showed no significant changes in CGRP 
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expression in vitro (Figures 11 and 12).  This suggests that BDNF-induced CGRP expression in 
DRG is mediated by the PLC-γ, but not by the PI3K/Akt or the MEK (ERK) pathway in culture. 
4.3 PLC-γ  mediates colitis-induced CGRP expression in DRG 
 
 Following in vitro inhibitor treatment, in order to determine the role of PLC-γ, 
immunohistochemical analysis showed an increase (p < 0.05) of PLC-γ protein in colitis-induced 
DRG (Figure 13). In order to ascertain whether CGRP protein and PLC-γ are related in response 
to BDNF treatment, co-localization was performed and it was demonstrated that the two proteins 
co-localized in small-diameter sensory neurons (Figure 14). To further investigate the role of 
PLC-γ on CGRP expression, colitis-induced animals were treated with U73122 in vivo. Results 
showed that U73122 significantly reduced (p<0.05) CGRP expression in sensory neurons of 
DRG during colitis (Figure 15).  Analysis of PLC-γ levels in colitis-induced DRG after treatment 
with anti-BDNF was conducted to inspect the upstream role of BDNF on PLC-γ activation. Anti-
BDNF significantly reduced (P < 0.05) levels of PLC-γ in DRG sensory neurons during colitis 
(Figure 16). 
4.4 The PI3K/Akt pathway is not activated in colitis-induced CGRP expression in DRG 
 
 In order to clearly distinguish the role of PI3K/Akt pathway from PLC-γ pathway in 
DRG, lack of co-localization of Akt and CGRP determined that PI3K/Akt pathway was not 
involved in signal transduction to CGRP gene expression (Figure 17).  Furthermore, in vivo 
treatment of LY294002 showed no significant change in CGRP protein expression (Figure 18).   
4.5 Association of CREB activation with CGRP expression in DRG 
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Co-localization was performed in order to determine if this transcription factor is 
associated with colitis-induced increase in CGRP protein expression. It was determined that 
activated CREB (pCREB) indeed co-localized with CGRP in small diameter DRG sensory 
neurons during colitis (Figure 19). 
4.6 CREB phosphorylation in DRG is regulated by endogenous and exogenous BDNF 
through the PLC-γ  pathway 
 
 To further investigate the phosphorylation of CREB during colitis, 
immunohistochemistry was performed on colitis-induced DRG for pCREB. pCREB significantly 
increased (p < 0.05) in TNBS7d DRG and this heightened response was reduced (p < 0.05) 
greatly by anti-BDNF (Figure 20). Further examination of the role of pCREB in downstream 
BDNF signaling was determined through exogenous BDNF treatment of DRG explants. Western 
blot analysis of time course revealed that pCREB increased (p < 0.05) significantly after five and 
10 minute BDNF treatment (Figure 21). In order to investigate the signaling pathways involved 
in upstream of CREB activation, DRG explants were treated with LY294002, PD98059, and 
U73122. Through western blot, it was shown that U73122 decreased BDNF-induced CREB 
activation, whereas LY294002 and PD98059 showed no significant change in CREB 
phosphorylation (Figure 22). 
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Figure 7. Changes in CGRP protein expression during colitis.  A. Immunohistochemistry 
displayed positively-stained CGRP cells in small diameter neurons. Arrows indicate positive 
staining. B. Analysis revealed that there is significant increase in CGRP protein expression in 
colitis-induced TNBS7d rats. Anti-BDNF decreased this heightened expression drastically. Bar = 
50µm. *, **, p<0.05. Results were obtained from 3 animals for each experimental group.  
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Figure 8. Changes in CGRP mRNA expression during colitis.  CGRP mRNA levels were 
analyzed using RT-PCR. Treatment of rat DRG with anti-BDNF significantly decreased TNBS-
induced inflation in CGRP mRNA. *, p<0.05. Results were obtained from 3 animals for each 
experimental group 
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Figure 9. Effects of BDNF on CGRP protein expression in vitro.  A. CGRP immunoreactivity 
in response to 16-hour treatment of 50ng/ml of BDNF on DRG explants. Arrows indicate 
positive staining. B. Evaluation of results revealed incubation with BDNF increased neurons 
positive for CGRP protein. Bar = 50µm. *, p<0.05. Results were obtained from 3 animals for 
each experimental group.  
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Figure 10. Effects of PLC inhibitor on CGRP protein expression in vitro.  A. CGRP staining 
in response to BDNF treatment with addition of PLC-γ inhibitor, U73122, in pair-matched DRG. 
Arrows indicate positive staining. B. In this in vitro treatment, there was a significant decrease in 
the number of neurons positive for CGRP. Bar = 25µm. *, p<0.05. Results were obtained from 3 
animals for each experimental group. 
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Figure 11. Effects of MEK kinase inhibitor on CGRP protein expression in vitro.  A. CGRP 
immunoreactivity in response to 50ng/ml of BDNF with addition of MEK kinase inhibitor, 
PD98059, in pair-matched DRG. Arrows indicate positive staining. B. Analysis showed no 
significant change in the number of neurons positive for CGRP. Bar = 25µm. Results were 
obtained from 3 animals for each experimental group.
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Figure 12. Effects of PI3K inhibitor on CGRP protein expression in vitro.  A. CGRP 
immunoreactivity in response to BDNF treatment with addition of PI3K inhibitor, LY294002, in 
pair-matched DRG. Arrows indicate positive staining. B. Results showed no significant change 
in cells positive for CGRP. Bar = 25µm. Results were obtained from 3 animals for each 
experimental group.
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Figure 13. PLC-γ expression during colitis in rat DRG.  A. Shown are neurons positive for 
PLC-γ in rat DRG treated with TNBS for seven days. Arrows indicate positive staining. B. 
Analysis determined that neurons positive for PLC-γ significantly increased in DRG of colitis-
induced rats. Bar = 50µm. *, p<0.05  Results were obtained from 3 animals for each 
experimental group 
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Figure 14. Co-localization of CGRP and PLC-γ.  Co-localization immunohistochemistry of 
PLC-γ and CGRP in L1 rat DRG following in vitro incubation with 50ng/ml  of BDNF. A. 
CGRP positively stained cells in DRG following incubation. B. PLC-γ positively stained neurons 
are also present in the DRG. C. Co-localization (shown by arrows) revealed that CGRP co-
localizes with PLC-γ. 
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Figure 15. PLC inhibitor treatment on CGRP protein expression in colitis.  A. CGRP 
immunoreactivity in response to in vivo PLC inhibitor treatment with a dose of 1-mg/kg body 
weight in colitis-induced rats. Arrows indicate positive staining. B. Analysis demonstrated 
significant decrease in positively stained neurons for CGRP. Bar = 50µm. *, p<0.05 Results were 
obtained from 3 animals for each experimental group. 
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Figure 16. PLC-γ during anti-BDNF treatment in colitis-induced rat DRG.  A. Shown are 
neurons positive for PLC-γ in rats treated with TNBS for seven days along with cells in response 
to co-treatment of TNBS7d and anti-BDNF. Arrows indicate positive staining. B. Results 
demonstrate neurons positive for PLC-γ significantly decreased in DRG of colitis-induced rats 
treated with anti-BDNF. Bar = 50µm. *, p<0.05  Results were obtained from 3 animals for each 
experimental group.
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Figure 17. Co-localization of CGRP and p-Akt.  Co-localization immunohistochemistry of p-
Akt and CGRP in L1 rat DRG following in vitro incubation with 50ng/ml BDNF. A. CGRP 
positively stained cells in DRG following incubation. B. p-Akt positively stained cells are also 
present. C. Co-localization (shown by arrows) revealed that CGRP did not co-localize with p-
Akt.  
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Figure 18. PI3K inhibitor treatment on CGRP protein expression in colitis.  A. Neurons 
stained for CGRP in response to in vivo PI3K inhibitor treatment (dose of 50 µg/kg body weight) 
in TNBS7d rats. Arrows indicate positive staining. B. Results showed no significant change in 
neurons positive for CGRP. Bar = 50µ. Results were obtained from 3 animals for each 
experimental group.  
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Figure 19. Co-localization of CGRP and p-CREB.  Co-localization immunohistochemistry of 
p-CREB and CGRP in L1 rat DRG following dissection from colitis-induced TNBS7d rats. A. 
CGRP positively stained cells in DRG following incubation. B. p-CREB positively stained 
neurons are also present in the DRG. C. Co-localization (shown by arrows) demonstrates that 
CGRP co-localizes with p-CREB.
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Figure 20. CREB phosphorylation during colitis.  A. Immunohistochemistry displayed 
positively-stained p-CREB cells in small diameter neurons. Arrows indicate positive staining. B. 
Analysis revealed that there is significant increase in CREB phosphorylation in colitis-induced 
TNBS7d rats. Anti-BDNF decreased this upsurge significantly. Bar = 50µm. *, **, p<0.05. 
Results were obtained from 3 animals for each experimental group.  
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Figure 21. Variations in CREB phosphorylation in DRG explants treated with BDNF A. 
and B. Western blot analysis of p-CREB determined that BDNF increases CREB 
phosphorylation significantly after five and ten minute incubation. *, p<0.05. Results were 
obtained from 3 animals for each experimental group.
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Figure 22. Upstream regulators of CREB phosphorylation in vitro. Western blot of 
pair-matched DRG treated five minutes with BDNF and a signaling pathway inhibitor. 
U73122 decreased p-CREB levels, whereas LY294002 and PD98059 showed no change. 
*, p<0.05. Results were obtained from 3 animals for each experimental group 
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Discussion 
 
 Inflammatory bowel disease is a chronic debilitating disease that causes 
inflammation and pain. This pain can be characterized by visceral hypersensitivity that 
increases sensitization of primary afferent sensory neurons to inflammatory signaling 
molecules and induces nociceptive transmission. In order to understand this mechanism of 
disease better, it is important to describe and outline the molecular mediators and their 
signaling pathways. The aim of this study was to identify the regulatory effects of BDNF 
on CREB phosphorylation and CGRP expression. CGRP and CREB are both signaling 
molecules that have been well identified to accompany nociceptive pain transmission. (64-
70)   
 In this study, colitis caused an increase in the levels of CGRP and pCREB in 
sensory neurons of DRG, which was attenuated by anti-BDNF and PLC inhibitor, U73122, 
but not PI3K inhibitor, LY294002. BDNF-induced CGRP expression and CREB activation 
in DRG culture was also blocked by PLC inhibitor, U73122, but not PI3K inhibitor, 
LY294002, or MEK kinase inhibitor, PD98059. This role of PLC-γ is further confirmed by 
the co-localization of CGRP with PLC-γ, but not phosph-Akt. CGRP and pCREB co-
localization indicate the regulatory role CREB transcription factor may play on CGRP 
mRNA transcription. These results suggest that the PLC-γ pathway, a unique pathway in 
signal transduction, is mediating BDNF action on sensory neuronal activation during 
colitis 
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Previous studies have shown that experimental animals induced with colitis show 
visceral hyperalgesia [62]. In these TNBS-induced animals, CGRP mRNA transcripts 
increase. For this study, TNBS animals were also treated with anti-BDNF and this resulted 
in an attenuation of CGRP mRNA. Increased CGRP protein expression also was attenuated 
with anti-BDNF. Previous studies demonstrated that BDNF increased in response to 
inflammation [71] and the results from this suggest that BDNF plays an important role in 
expression of the important nociceptive pain marker, CGRP.  To examine the role of 
BDNF in CGRP protein expression more carefully, lumbosacral DRG were explanted from 
rat spinal cord and incubated with BDNF. Immunohistochemical analysis revealed the 
CGRP protein levels increased, demonstrating the BDNF-CGRP link with in vitro studies. 
BDNF thus is an important regulator in CGRP protein expression and sensory pain 
transmission. It has been demonstrated that there is a NGF-CGRP signaling axis and 
analysis of the results presented show a parallel signaling axis between BDNF and CGRP. 
It has been shown that NGF can increase CGRP and that NGF also is able to increase 
BDNF in DRG. This relationship with current results implies that NGF can increase CGRP 
through its own receptor, TrkA, or NGF can mediate BDNF regulation upregulation, which 
can induce CGRP expression through its receptor TrkB.  
BDNF knockout mice have previously shown to have lower mucosal nerve fiber 
density and also lower visceral hypersensitivity to colonic distension [72].  Similarly, 
CGRP knockout mice are unable to induce visceral hypersensitivity [51]. Attenuation of 
CGRP and pCREB with anti-BDNF is consistent with these studies and provides a 
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mechanistic exploration underlying BDNF’s role in synaptic plasticity and remodeling 
during visceral inflammation.  
Furthermore, to determine the signaling mechanism behind these regulatory 
changes, explants were treated with various signaling pathway inhibitors as well as BDNF 
to determine if inhibition of a signaling molecule led to attenuation of BDNF effects on 
CGRP protein.  Inhibition of the PLC-γ pathway, but not the PI3K/Akt or MAPK 
pathways, led to decreased CGRP protein expression and CREB activation both in vivo 
and in vitro. CGRP also co-localizes with PLC-γ and CREB in sensory neuron cells of L1 
DRG, whereas p-Akt did not positively co-localize with CGRP. These results suggest a 
novel mechanism through which BDNF influences sensory neuron activation. Studies have 
shown that BDNF-up-regulation is triggered by increase in NGF signaling through the 
PI3K/Akt pathway [71]. However, results suggest that BDNF itself works to activate 
CREB through the PLC-γ pathway.  PLC-γ can be activated by receptor tyrosine kinase 
phosphorylation and can also regulate Ca2+ entry that may affect the activation of various 
transcription factors, such as CREB. This pathway is crucial in neuronal plasticity in CNS 
signaling and LTP. The role of the PLC-γ/Ca2+ in visceral hypersensitivity has not been 
explored and this finding suggests the PLC-γ pathway is critical in peripheral neuronal 
plasticity in response to visceral inflammation. 
 The PLC-γ pathway may regulate CREB in this signaling axis and to further 
investigate the intrinsic mechanism, levels of pCREB were observed in relationship to 
BDNF. BDNF increased pCREB protein in vitro and in colitis. Through in vitro treatment 
of DRG with PLC inhibitor, it was discovered that the treatment decreased activation of 
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CREB. MEK kinase inhibitor and PI3K inhibitors showed no change. The PLC-γ-mediated 
CREB phosphorylation can be triggered by PLC-γ-modulated Ca2+ release or influx and 
further activation of Ca+ dependent kinase activation, such as Calcium/calmodulin-
dependent protein kinase II (CaMKII). PLC-γ can induce this Ca2+ increase through 
cleavage of phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2) into diacyl glycerol 
(DAG) and inositol 1,4,5-trisphosphate (IP3). IP3 can then bind to IP3 receptors, namely 
Ca2+ channels in the smooth endoplasmic reticulum. DAG functions to activate PKC, 
which in turn activates other molecules that alter cellular activity. Therefore, PLC-γ 
pathway is a novel mechanism in response to visceral inflammation that modulates many 
secondary messengers in activation of a number of transcription factors, one possibility 
being CREB.  
In conclusion, these results demonstrate that there is a BDNF-CREB-CGRP 
signaling axis that accompanies inflammation and plays a role in visceral hypersensitivity. 
The regulation of CREB and CGRP by BDNF leads to nociceptive pain transmission 
through activation of CREB, alteration in gene transcription and protein synthesis, and 
delivery of transmitter neuropeptides to nerve terminals. 
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